Latest news with #CelecoxibCapsules
Mint
16-07-2025
- Business
- Mint
Stocks to watch: Tech Mahindra, HDFC Life, Dixon Tech, Bajaj Finserv among shares in focus today
Shares of Tech Mahindra, ITC Hotels, Angel One will be in focus as companies will declare Q1 results. The company posted a 14.4% year-on-year increase in net profit for the first quarter of FY26, with the profit rising to ₹ 547 crore from ₹ 478 crore in the same period last year. HDB Financial Services posted a slight drop in net profit for the first quarter of FY26, with its profit after tax standing at ₹ 568 crore — a 2% decrease from ₹ 582 crore recorded in the corresponding quarter of the previous year. Dixon Technologies has signed a binding term sheet to acquire a 51% ownership stake in Kunshan Q Tech Microelectronics Zydus Life has received final approval from the USFDA for its Celecoxib Capsules, which are used to relieve pain and inflammation associated with various conditions, including arthritis. The Insurance Regulatory and Development Authority of India (IRDAI) has given the green light for the transfer of 26% equity stake held by Allianz SE in its two insurance joint ventures—Bajaj Allianz General Insurance and Bajaj Allianz Life Insurance—to Bajaj Finserv, Bajaj Holdings & Investment (a promoter), and Jamnalal Sons (a promoter group entity). The local search engine posted a 13% year-on-year rise in net profit, reaching ₹ 160 crore for the quarter ended June 30, 2025. The bank declared a 10-basis-point cut in its Marginal Cost of Funds-Based Lending Rate (MCLR) for all loan durations. Biocon Biologics, a subsidiary of Biocon, has received approval from the US FDA for KIRSTY (Insulin Aspart-xjhz), 100 units/mL, marking it as the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Phani Shankar has stepped down from his role as President and Chief Credit Officer (Senior Management Personnel) of the bank. His resignation will take effect on July 21. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
15-07-2025
- Business
- Business Standard
Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules
Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib Capsules, marking another addition to its growing U.S. generics portfolio. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body. It is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain. It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old. Celecoxib capsules will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. According to IQVIA MAT data (May 2025), Celecoxib Capsules recorded annual sales of approximately USD 122.6 million in the U.S. market. With this approval, Zydus has now secured a total of 428 final approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since it began its U.S. regulatory filing process in FY 200304. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. The counter shed 0.14% to Rs 967.15 on the BSE.
Business Upturn
30-04-2025
- Business
- Business Upturn
Strides Pharma receives USFDA approval for Celecoxib Capsules
By Aman Shukla Published on April 30, 2025, 15:09 IST Strides Pharma Science Limited announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has received approval from the United States Food & Drug Administration (USFDA) for Celecoxib Capsules in 100 mg, 200 mg, and 400 mg strengths. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex® (Celecoxib) Capsules, manufactured by Upjohn US 2 LLC. This approval allows Strides to expand its offerings in the anti-inflammatory therapeutic area. Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) and a selective COX-2 inhibitor. It is used in the treatment of various conditions including osteoarthritis, rheumatoid arthritis, acute pain, and primary dysmenorrhea. According to data from IQVIA (IMS), the combined U.S. market size for Celecoxib Capsules across all approved strengths is approximately USD 116 million. Strides will manufacture the approved Celecoxib Capsules at its facility located in Puducherry, India. This development adds to Strides Pharma's generic product portfolio for the U.S. market and supports its strategy of providing cost-effective treatment options in the anti-inflammatory segment. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
